Skip to content
Screener

Prime Medicine PRME Q2 2025 earnings

Reported August 7, 2025 · Before market open

Revenue$1.1MMiss by $1.7M
EPS-$0.41Miss by $0.05
Revenue estimate$2.8M
EPS estimate-$0.36

Next report

Nov 6, 2026 (in 2 months)
Revenue estimate$1.3M
EPS estimate-$0.23

Financials

Q2 2025

Income statement

See full
Revenue$1.1M—
Operating income-$53.4M+4.1%
Net income-$52.6M+4.9%
EPS (diluted)-$0.41+10.9%

Balance sheet

See full
Cash & equivalents$67.5M-2.3%
Total debt$119.7M+188%
Total equity$60.9M-69.0%
Total assets$279.0M+7.4%

Cash flow

See full
Operating cash flow-$41.4M+9.0%
CapEx$1.6M-17.4%
Free cash flow-$43.0M+9.3%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$283.6M-53.7%
Enterprise value$335.84M-42.6%
P/S57.2×-979×

Profitability

See full
Operating margin-4,116.6%-1,940pp
Net margin-4,016.8%-1,892pp

Returns & leverage

See full
Return on equity-154.8%+193pp
Debt / equity2×+1.8×
Current ratio3.6×-4.7×

Segments

By segment

See full
Reportable Segment$1.1M—

FAQ

When did Prime Medicine report Q2 2025 earnings?
Prime Medicine (PRME) reported Q2 2025 earnings on August 7, 2025 before market open.
What were Prime Medicine's Q2 2025 revenue and EPS?
Prime Medicine reported revenue of $1.1M and eps of $-0.41 for Q2 2025.
Did Prime Medicine beat estimates in Q2 2025?
Revenue missed the consensus estimate of $2.8M by $1.7M. EPS missed the consensus estimate of $-0.36 by $0.05.
How did Prime Medicine's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 97.0% from $37.8M a year earlier and eps grew 10.9% from $-0.46.
Where can I find Prime Medicine's Q2 2025 SEC filings?
You can read the 8-K earnings release (0001628280-25-037840) and the 10-Q periodic report (0001628280-25-038619) directly on SEC EDGAR. The filing index links above go to sec.gov.